NZ759411A - Pharmaceutical compositions comprising dimethyl fumarate - Google Patents

Pharmaceutical compositions comprising dimethyl fumarate

Info

Publication number
NZ759411A
NZ759411A NZ759411A NZ75941114A NZ759411A NZ 759411 A NZ759411 A NZ 759411A NZ 759411 A NZ759411 A NZ 759411A NZ 75941114 A NZ75941114 A NZ 75941114A NZ 759411 A NZ759411 A NZ 759411A
Authority
NZ
New Zealand
Prior art keywords
dimethyl fumarate
pharmaceutical compositions
starch
compositions
gastro
Prior art date
Application number
NZ759411A
Other languages
English (en)
Inventor
Jimenez Maria Planells
Lopez Begoña Duarte
Coll Pere Guiro
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ759411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of NZ759411A publication Critical patent/NZ759411A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ759411A 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate NZ759411A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12
NZ720287A NZ720287A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Publications (1)

Publication Number Publication Date
NZ759411A true NZ759411A (en) 2020-06-26

Family

ID=49917530

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ759411A NZ759411A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate
NZ720287A NZ720287A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ720287A NZ720287A (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Country Status (31)

Country Link
US (2) US20160310457A1 (enExample)
EP (2) EP3079666B1 (enExample)
JP (3) JP6581088B2 (enExample)
KR (2) KR102335289B1 (enExample)
CN (2) CN105813634A (enExample)
AR (1) AR098746A1 (enExample)
AU (2) AU2014363792B2 (enExample)
BR (1) BR112016012179B1 (enExample)
CA (2) CA3135273A1 (enExample)
CL (1) CL2016001415A1 (enExample)
CY (1) CY1124336T1 (enExample)
DK (1) DK3079666T3 (enExample)
EA (1) EA201600457A1 (enExample)
ES (1) ES2860551T3 (enExample)
HR (1) HRP20210468T1 (enExample)
HU (1) HUE054408T2 (enExample)
IL (2) IL287109B (enExample)
LT (1) LT3079666T (enExample)
MX (2) MX375144B (enExample)
MY (1) MY179355A (enExample)
NZ (2) NZ759411A (enExample)
PH (2) PH12016501043A1 (enExample)
PL (1) PL3079666T3 (enExample)
PT (1) PT3079666T (enExample)
RS (1) RS61658B1 (enExample)
SG (3) SG10201913076PA (enExample)
SI (1) SI3079666T1 (enExample)
SM (1) SMT202100205T1 (enExample)
TW (2) TWI704915B (enExample)
UA (2) UA123880C2 (enExample)
WO (1) WO2015086467A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
EP3501510B1 (en) 2014-02-28 2020-07-01 Banner Life Sciences LLC Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3302461A4 (en) 2015-06-01 2019-02-13 Sun Pharmaceutical Industries Ltd PHARMACEUTICAL COMPOSITIONS OF DIMETHYLFUMARATE
WO2016205701A1 (en) 2015-06-19 2016-12-22 University Of Southern California Enteral fast access tract platform system
CA2990230A1 (en) 2015-06-19 2016-12-22 University Of Southern California Compositions and methods for modified nutrient delivery
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
CN108472260B (zh) * 2015-12-31 2021-08-10 波尔法玛制药工厂股份公司 用于制备包括富马酸二甲酯的肠溶包衣颗粒的方法
WO2017129370A1 (en) * 2016-01-28 2017-08-03 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
BR112018016300A2 (pt) * 2016-02-12 2018-12-26 Univ Zuerich fumarato de dimetila (dmf) para prevenção ou tratamento de gota, acne, diabetes, vitiligo e/ou pioderma gangrenoso
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
KR20200018458A (ko) 2017-06-23 2020-02-19 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학 조성물
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
MX2021012441A (es) * 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.
CA3158394A1 (en) * 2019-11-07 2021-05-14 Asahi Kasei Kabushiki Kaisha Cellulose composition and tablet
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
KR20220133807A (ko) * 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
WO2022212893A1 (en) * 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
PL2801354T3 (pl) * 2004-10-08 2017-08-31 Forward Pharma A/S Kompozycje farmaceutyczne o kontrolowanym uwalnianiu zawierające ester kwasu fumarowego
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
ATE461701T1 (de) * 2005-04-28 2010-04-15 Wyeth Corp Mikronisiertes tanaproget und zusammensetzungen damit
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
US20080299196A1 (en) 2005-10-07 2008-12-04 Aditech Pharma Ab Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
US20120034274A1 (en) 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
RU2743637C2 (ru) 2009-01-09 2021-02-20 Фвп Ип Апс Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице
EP3318249A1 (en) * 2009-04-29 2018-05-09 Biogen MA Inc. Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis
US20120308562A1 (en) * 2011-06-03 2012-12-06 Derynck Mika K Methods of treating mesothelioma with a pi3k inhibitor compound
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
PE20150092A1 (es) * 2012-02-07 2015-02-06 Biogen Idec Inc Composiciones farmaceuticas que contienen fumarato de dimetilo

Also Published As

Publication number Publication date
ES2860551T3 (es) 2021-10-05
PH12016501043B1 (en) 2016-07-04
TWI704915B (zh) 2020-09-21
US20210330628A1 (en) 2021-10-28
LT3079666T (lt) 2021-03-25
KR20210150587A (ko) 2021-12-10
SG10201913076PA (en) 2020-02-27
UA120428C2 (uk) 2019-12-10
CN114159421A (zh) 2022-03-11
EP3079666B1 (en) 2021-02-03
PT3079666T (pt) 2021-02-18
CN105813634A (zh) 2016-07-27
HRP20210468T1 (hr) 2021-05-14
MX375144B (es) 2025-03-06
IL287109B (en) 2022-08-01
MX2016007105A (es) 2016-08-11
PH12019502610A1 (en) 2021-02-22
IL245685B (en) 2021-10-31
CA3135273A1 (en) 2015-06-18
AU2019268075A1 (en) 2019-12-12
UA123880C2 (uk) 2021-06-16
BR112016012179A2 (enExample) 2017-08-08
SG10201802815UA (en) 2018-05-30
JP2019218385A (ja) 2019-12-26
PL3079666T3 (pl) 2021-09-06
CA2932054C (en) 2022-09-20
TWI687218B (zh) 2020-03-11
EP3079666A1 (en) 2016-10-19
US20160310457A1 (en) 2016-10-27
IL287109A (en) 2021-12-01
AU2014363792B2 (en) 2019-11-14
MY179355A (en) 2020-11-05
AU2019268075B2 (en) 2020-12-17
PH12016501043A1 (en) 2016-07-04
TW201605435A (zh) 2016-02-16
KR20160089397A (ko) 2016-07-27
EA201600457A1 (ru) 2016-11-30
HUE054408T2 (hu) 2021-09-28
JP6581088B2 (ja) 2019-09-25
BR112016012179B1 (pt) 2023-04-18
JP6945603B2 (ja) 2021-10-06
CL2016001415A1 (es) 2017-01-20
DK3079666T3 (da) 2021-03-22
SMT202100205T1 (it) 2021-07-12
AU2014363792A1 (en) 2016-06-09
NZ720287A (en) 2020-05-29
SG10201913080VA (en) 2020-03-30
HK1224212A1 (en) 2017-08-18
AR098746A1 (es) 2016-06-08
TW202011953A (zh) 2020-04-01
JP2016540003A (ja) 2016-12-22
IL245685A0 (en) 2016-06-30
JP2021130689A (ja) 2021-09-09
SI3079666T1 (sl) 2021-04-30
EP3656379A1 (en) 2020-05-27
KR102353201B1 (ko) 2022-01-18
CA2932054A1 (en) 2015-06-18
KR102335289B1 (ko) 2021-12-06
MX2020009745A (es) 2020-10-08
CN114159421B (zh) 2023-08-25
CY1124336T1 (el) 2022-07-22
RS61658B1 (sr) 2021-04-29
WO2015086467A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
PH12019502610A1 (en) Pharmaceutical compositions comprising dimenthyl fumarate
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
GB2547397A (en) Configuration based cache coherency protocol selection
EP4349406A3 (en) Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole for use as a medicament
EA201790785A1 (ru) Производные тетрагидроизохинолина
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
EP3080139A4 (en) A process for the preparation of regadenoson
EP3096775A4 (en) Socs mimetics for the treatment of diseases
EP3593265B8 (en) Controlling user access to a medical system
EP3033053A4 (en) Bioresorbable scaffold for treatment of bifurcation lesion
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EP3024326A4 (en) Novel process for the preparation of levothyroxine sodium
PH12015502703A1 (en) Pharmaceutical compositions
IL256812A (en) Heteroaryl carbonitriles for the treatment of disease
EP3189847A4 (en) Therapeutic or prophylactic agent for itching skin diseases
AU2018904527A0 (en) Low latency inter-processor signalling
HK1216150A1 (zh) 匹多莫德治疗炎症性肠病的用途
HK1216151A1 (zh) 匹多莫德治疗肠易激综合症的用途
HK1248142A1 (en) Tofacitinib orally disintegrating tablets
SI3413894T1 (sl) Uporaba inhibitorjev aktivnosti ali funkcije PI3K za zdravljenje primarnega sjoegrenovega sindroma
AU2015905202A0 (en) Orthopaedic Bunion Splint
HK1240849A1 (en) Heparan sulfate biosynthesis inhibitors for the treatment of diseases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2021 BY COMPUTER PACKAGES INC

Effective date: 20201118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2022 BY COMPUTER PACKAGES INC

Effective date: 20211117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2023 BY COMPUTER PACKAGES INC

Effective date: 20221117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2024 BY COMPUTER PACKAGES INC

Effective date: 20231117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2025 BY COMPUTER PACKAGES INC

Effective date: 20241117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 DEC 2026 BY COMPUTER PACKAGES INC

Effective date: 20251126